Jiangsu Hengrui Pharmaceuticals (01276): Approval granted to conduct clinical trials for injection of lysozyme microspheres.

Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., has recently received approval from the National Medical Products Administration for the clinical trial of Leuprorelin Acetate Microspheres for injection. The clinical trial will be conducted soon. Leuprorelin Acetate is a GnRH analogue used for the treatment of prostate cancer. The research product LEUPLINPro was developed by Takeda Pharmaceutical Company Limited and was approved for marketing by PMDA in Japan in November 2015, but has not been marketed domestically in China. The usage and dosage of this product is different from the Leuprorelin Microspheres for injection already on the market in China, as it is a generic version of an overseas original drug that has not been marketed domestically. As of now, the cumulative research and development investment in the Leuprorelin Acetate Microspheres for injection project is approximately 24.68 million yuan.